Humour: an essential tool in cancer care and communication
“I don’t know what I’ll find in there. It could be cancer. In the best case, you’ll be stuck with a bag for the rest of your life.” Those are the words Paweł Grabowski, a fit and health-conscious 48-year-old from…
Academic publishing is a maze of tests and barriers for patients as researchers and readers
Once solely engaged as participants in academic studies and research, patients are increasingly becoming more involved at several stages of the research process. From helping large organisations assess grants and…
Young-onset digestive cancers: this is how we improve the quality of care
“I had very severe symptoms. I had jaundice, I had itching – symptoms that could definitely indicate something related to the liver, or quite severe disease – but because of…
NEWS
Second-generation BTK inhibitor shows promise as fixed-duration therapy in CLL
Treatment with the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib plus the BCL2 inhibitor venetoclax (with or without the CD20 inhibitor obinutuzumab), delivered as fixed-duration therapies, significantly improved progression free survival in comparison with standard-of-care chemotherapy in previously untreated patients…
Discover the upcoming SPCC events on the OncoCorner platform
CONTENTS
ARTICLES
Europe’s cancer agenda: how we keep it a priority in changing times
“I feel I’m among friends… we are all fighting the same battles.” This is how the former European Health Commissioner Stella Kyriakides greeted her audience at the European Cancer Summit at a session on November 20th devoted to her great…
